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Abstract
Background: Carbapenemase-producing Enterobacteriaceae (CPE), particularly carbapenemase-producing Klebsiella
pneumoniae isolates, are important causative agents of nosocomial infections associated with significant mortality
rates mostly in critical wards. The rapid detection and typing of these strains is critical either for surveillance purposes
and to prevent outbreaks and optimize antibiotic therapy. In this study, the MALDI-TOF MS method was used to detect
rapidly these isolates from blood cultures (BCs) and to obtain proteomic profiles enable to discriminate between
carbapenemase-producing and non-carbapenemase-producing strains.
Results: Fifty-five K. pneumoniae strains were tested. Identification and carbapenemase-production detection assay
using Ertapenem were performed both from bacterial pellets extracted directly from BCs flasks and from
subcultures of these strains. For all isolates, a complete antimicrobial susceptibility testing and a genotypic
characterization were performed.
We found 100% agreement between the carbapenemase-producing profile generated by MALDI TOF MS and
that obtained using conventional methods. The assay detected and discriminated different carbapenemase-producing
K. pneumoniae isolates within 30 min to 3 h after incubation with Ertapenem.
Conclusions: MALDI-TOF MS is a promising, rapid and economical method for the detection of carbapenemase-
producing K. pneumoniae strains that could be successfully introduced into the routine diagnostic workflow of clinical
microbiology laboratories.
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Background
In recent years, there was a worldwide spread of
carbapenemase-producing Enterobacteriaceae (CPE),
mainly carbapenemase-producing Klebsiella pneumo-
niae isolates, that has become an increasing health
care problem all over the world [1–3]. CPE are im-
portant etiological agents of hospital-acquired infections
(HAI), which cause significant mortality particularly
among patients in intensive care units (UCI) [4]. In
Enterobacteriaceae, carbapenem resistance, (CRE), is
mainly induced by two mechanisms: (i) expression of car-
bapenemases enzymes able to degrade carbapenems; (ii)
an association of decreased outer membrane permeability
(e.g porin loss or deficiency of porin expression) with
overexpression of β-lactamases possessing very weak car-
bapenemase activity (e.g extended-spectrum β-lactamases
ESBLs or acquired AmpC-type cephalosporinases) [5].
From a public health standpoint, carbapenemase producers
are taken into major consideration than carbapenem-
resistant isolates non carbapenemase producers because
their resistance trait can be transferred [6]. The carbapene-
mase genes transmission by mobile genetic elements leads
to a rapid dissemination and carries additional non-β-
lactam resistance determinants responsible for resistance to
different groups of antibiotics giving rise to multidrug- and
pandrug-resistant (MDR, PDR) isolates [7]. Accordingly, a
rapid detection of carbapenemases is essential in order to
prevent spreading, detect outbreak and for an effective
antibiotic therapy to improve the outcome of these patients.
However, detection of carbapenemases in Enterobacteria is
challenging especially in the presence of carbapenemase-
producing Klebsiella pneumoniae strains with low
carbapenem MICs [8]. For that purpose, the latest molecu-
lar- and biochemical-based techniques (e.g RT-PCR, micro-
array, Carba NP test) have been shown to be suitable to
detect early (3–5 h) carbapenemase-producing Enterobac-
teria directly from positive blood cultures [9–13]. Recently,
it has been shown that MALDI-TOF MS could represent
an alternative to detect rapidly CPE strains as well as to
identify rapidly the pathogens [14–17]. As mass spectrom-
etry measures mass differences, a MALDI-TOF MS-based
assay was performed to detect the hydrolysis of different
β-lactam antibiotics after a short co-incubation of the
Gram-negative isolate with the specific antibiotic. There-
fore, hydrolyzed and non-hydrolyzed substances which dif-
fer in their molecular weights could be monitoring [15, 17].
In this study, 55 consecutive non-replicated clinical
strains of K. pneumoniae, isolated from hospitalized
patients with Gram-negative bacteremia were tested. The
study focused on carbapenemase-producing Klebsiella
pneumoniae strains because of their increasing prevalence
in Italian hospitals [18]. The identification and the
carbapenemase-production detection assay using Ertape-
nem were performed from both bacterial pellets extracted




A total of 55 consecutive non-replicated clinical strains of
K. pneumoniae, isolated from blood cultures of hospital-
ized patients, were collected from July 2014 to July 2015
in two hospitals of Rome, Italy. In particular, 47 were
isolated at the Microbiology Laboratory of Polyclinic “Tor
Vergata” Foundation and 8 at the Clinical Pathology and
Microbiology Laboratory of the University Hospital
“Campus Bio-Medico”.
The blood specimens were collected in BD BACTEC™
Plus Aerobic/F and BD BACTEC™ Plus Anaerobic/F
vials and incubated in a Bactec FX blood culture system
(Becton Dickinson, NJ, USA). Clinical and epidemio-
logical data of patients were also recorded. The isolates
were collected for surveillance and public health pur-
poses, as done routinely in clinical setting, and no eth-
ical approval was required.
Sample preparation
At the Microbiology laboratory of Polyclinic “Tor Ver-
gata” Foundation, a total of 170 consecutive positive BCs
containing Gram-negative rods were included in this
study. After the BC was flagged as positive, Gram
staining was performed. In the presence of Gram-
negative rods, MALDI-TOF MS identification was
performed directly from the bacterial pellet extracted from
the BC flasks, using the MALDI Sepsityper kit (Bruker
Daltonics, Bremen, Germany), according to the manufac-
turer’s instructions, in an autoflex speed mass spectrometer
(Bruker Daltonics, Bremen, Germany). Moreover, an add-
itional bacterial pellet was extracted for the carbapenemase-
production detection assay.
For the identification assay, an ethanol-formic acid
extraction was performed on the bacterial pellets ob-
tained using the Sepsityper kit (pellets contained 107 to
109 CFU), according to manufacturer’s instructions.
In the Clinical Pathology and Microbiology laboratory
of the University Hospital “Campus Bio-Medico”, only
the MALDI-TOF MS identification was performed dir-
ectly from the bacterial pellet extracted from the BC
flaks using the MALDI Sepsityper kit (Bruker Daltonics,
Bremen, Germany) as described above, on a Microflex
LT mass spectrometer (Bruker Daltonics, Bremen,
Germany). However, the carbapenemase-production de-
tection assay for the same isolates was performed only
from subcultures of frozen strains at the Microbiology
laboratory of Polyclinic “Tor Vergata” Foundation on an
autoflex speed mass spectrometer (Bruker Daltonics,
Bremen, Germany).
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MALDI-TOF MS-based carbapenemase-production
detection assay
The bacterial pellets obtained using the Sepsityper kit
(pellets contained 107 to 109 CFU) were resuspended in
30 μl of Ertapenem solution (1 mg/mL in 1 mM ammo-
nium hydrogen citrate buffer pH 7.1) and incubated for
3 h at 37 °C under agitation for the carbapenemase-
production detection assay. Incubated suspensions with
Ertapenem solution were centrifuged at 13.000 rpm for
2 min, and 1 μl of the supernatant was spotted in quad-
ruplicate onto a polished steel target plate MTP 384 and
air-dried spots were overlaid with 1 μl of HCCA matrix
in organic solvent. Data are collected at 30-min intervals
during the entire incubation time. All measurements
were performed on an autoflex speed mass spectrometer
(Bruker Daltonics, Bremen, Germany), within a mass
range of 100 to 1.100 Da, while the spectra were manu-
ally examined using the FlexAnalysis 3.4 software
(Bruker Daltonics, Bremen, Germany). The spectra were
acquired in the linear positive mode at a laser frequency
of 200 Hz. A method optimized for the low mass range
was set up using the following parameters: acquisition
range, 100 to 1,000 Da with maximum laser frequency;
acceleration voltage, IS1 voltage 19.66 kV; IS2 voltage,
18.51 kV; lens 6.99 kV and extraction delay time, 350 ns.
For instrument calibration, an external standard solution
consisting of bradykinin 1–7 (757.40 Da), 2 HCCA peaks
(CCA_[M +H]+ 190.05 Da; and CCA_[2 M +H]+
379.02 Da) and angiotensin (1049, 54) (Bruker Daltonics,
Bremen, Germany) (100–1000 Da range) was used. A
reference wild-type strain of K. pneumoniae was used as
a negative control while a KPC-producing K. pneumo-
niae reference strain was used as a positive control and
both of them were included in each run.
For quality control of the antibiotic solution and for
detection of spontaneous hydrolysis a sample with
Ertapenem solution only, without bacteria, was proc-
essed as all the other samples.
The obtained spectra were not reported in this section
because they are periodically deleted for room reasons
from the computer used for the routine laboratory
analyses.
Subcultures processing
Identification and the carbapenemase-production detec-
tion assay were also performed from subcultures of the
strains isolated on MacConkey agar, Columbia blood
agar and Chocolate PolyViteX plates (BioMèrieux,
France) after 18–24 h incubation at 37 °C. After
overnight incubation, 30 μl of Ertapenem solution was
inoculated separately with a 1 μl-inoculation loop filled
with both single bacteria colonies isolated from
overnight cultures and control strains and incubated for
3 h at 37 °C under agitation for the carbapenemase-
production detection assay. For the identification assay,
a small part of an isolate’s colony was inoculated on the
polished steel target plate MTP 384 and overlaid with
1 μl of HCCA matrix. In the same manner, the respect-
ive measurements were performed as described above.
Strain characterization
For all K. pneumoniae isolates, a complete antimicrobial
susceptibility testing was created from isolates cultured
onto chocolate PolyViteX agar after overnight incuba-
tion at 37 °C using the Vitek 2 automated system
(bioMérieux, France) and the AST cards N-202 for a
phenotypic characterization. The MIC values were
interpreted according to EUCAST breakpoints tables
2014. A genotypic characterization for the resistance
genes blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP, blaSHV,
blaTEM, blaCTX-M,was performed by Polymerase Chain
Reaction (PCR) (Qiagen, Hilden, Germany), using
primers already reported in literature [11, 17]. The DNA
was extracted from each isolated strain by EZI Advanced
XL automated system (Qiagen, Hilden, Germany).
Results
MALDI-TOF MS identification performance
At the Microbiology laboratory of Polyclinic “Tor Ver-
gata” Foundation, 175 isolates, tested directly from blood
culture samples, were correctly identified at the species
level by MALDI-TOF MS; there was a 100% agreement
with the subculture MALDI-TOF MS-based identifica-
tion routinely performed in our laboratory. One-
hundred and forty-six isolates fell into the Enterobacteri-
aceae family whereas 29 were non fermentative Gram-
negatives rods. Among the Enterobacteriaceae isolates,
47 were identified as K. pneumoniae strains. All identifi-
cations exhibited a Biotyper score value of > 2.2. More-
over, the identifications obtained directly from blood
culture samples had a score values >2.3 compared with
the score obtained from subculture. Data, using the dir-
ect method, were obtained earlier respect to the routine
method: 15 min after the BC was flagged as positive ver-
sus 12 h of the routine method.
MALDI-TOF MS-based carbapenemase-production detec-
tion assay performance
Data were collected at 30-min intervals during the entire
incubation time. Differences in the hydrolysis rate were
easily detected. In the presence of sensitive K. pneumo-
niae strains, intact Ertapenem displayed the following
peak pattern: 476.5 Da, 498.5 Da, 520.5 Da, correspond-
ing to the molecular peak of Ertapenem, its single so-
dium adduct and its double sodium adduct, respectively.
These peaks were not found in the spectra obtained
from carbapenemase-producing strains. Instead, a mass
peak was found at 472.5 Da corresponding to the
Sakarikou et al. BMC Microbiology  (2017) 17:54 Page 3 of 8
hydrolyzed decarboxylated sodium adduct while another
peak was found at 538.5 Da corresponding to the hydro-
lyzed double sodium adduct [19]. A m/z 450 Da peak
was also detectable in all spectra. Ertapenem only was
also incubated up to 3 h as quality control and no spon-
taneous hydrolysis was seen. Moreover, no difference
was observed when the carbapenemase-production de-
tection assay was performed either on solid media
growth isolates or isolates extracted directly from BCs.
Thus, sensitivities and specificities were 100% for both
subcultures and blood cultures. Furthermore, the assay
revealed and discriminated KPC-producing strains from
other carbapenemases after a 30 min incubation with
Ertapenem (Fig. 1). Thus, KPC- plus VIM- producing
strains were detected after 2 h incubation with Ertape-
men while OXA-48-producing strains were detected
after 3 h incubation with Ertapenem. However, after 1 h
incubation a partial hydrolysis of Ertapenem was ob-
served in the presence of OXA-48 strains as indicated
by the loss of its molecular peak in the presence of the
peaks of its salt adducts.
Carbapenemase production was detected by MALDI-
TOF MS, and these results were compared with those
achieved by routine methods, MIC determination and
PCR analysis. No discordance was observed in terms of
bacteria classification according to resistance profile
(Table 1). Of the 55 isolates investigated, 40 were found
to be carbapenemase-producing strains and 15 non-
carbapenemase-producing strains.
Considering the time to results, the report of the
MALDI-TOF-based assay was available after 3 h the BCs
were flagged as positive. Instead, 12 to 24 h were neces-
sary using the routine AST, and 5 h by PCR assay. So,
the time saved for generating the report ranged from 11
to 21 h comparing MALDI-TOF vs routine AST and 2 h
comparing MALDI-TOF with PCR assay.
Discussion
Antibiotic resistance in CPE is a life-threatening condi-
tion, so a prompt diagnosis is crucial for improving pa-
tient’s prognosis, choose the optimal antibiotic therapy
and implement surveillance network. In this context,
molecular typing helps to define the extent of the out-
break, identify the source of infection and the reservoir
[20, 21], while proteomic profiling may represent a valid
Fig. 1 Mass Spectra of non-hydrolyzed and hydrolyzed Ertapenem and mass spectra of Ertapenem degradation after incubation with KPC, KPC
plus VIM and OXA-48 producing K. pneumoniae strains at different time points, respectively. Molecular weight values of Ertapenem and its salt
adducts peaks are indicated at the top of the peaks
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alternative to biochemical and genome-based identifica-
tion and susceptibility detection assays.
In this study, we examine the performance of MALDI-
TOF MS identification assay and the mass spectrometric
carbapenemase-production detection assay directly on
positive BC flasks from hospitalized patients with Gram-
negative bacteremia. The MALDI-TOF MS technology
appeared accurate, cost saving and rapid.
It was investigated the Ertapenem hydrolysis induced
by different carbapenemase-producing K. pneumoniae
strains isolated from positive blood cultures. Using 1 mL
of blood culture fluid, the obtained amount of bacteria
producing carbapenemase was sufficient to hydrolyze
the antibiotic in a time frame ranging from 30 min to
3 h of incubation. The different peak patterns derived
from carbapenemase and non-carbapenemase-producing
strains allowed the unequivocal identification of these
strains. All spectra displayed a mass peak at 450 Da cor-
responding to the hydrolyzed and decarboxylated forms
of Ertapenem. Likely, this peak reflects an unspecific
signal derived from a slight background hydrolysis.
Similarly, the mass peak at 460 Da detected in all spec-
tra, except those of Ertapenem solution alone, is prob-
ably another unspecific signal derived from the blood
culture medium [19]. For these reasons, these two peaks
were not classified among the spectra originated from
BCs (Fig. 1).
A characteristic peak pattern that allowed the discrim-
ination between the carbapenemase-producing and non-
carbapenemase-producing plated bacteria was also
obtained with the bacteria derived directly from fresh
positive BCs. Therefore, it can be envisaged that the
growth medium does not affect significantly the activity
of the carbapenemase enzymes.
The method presented in this work does not require
particularly skilled personnel, and may be used in any la-
boratory equipped with a MALDI-TOF spectrometer.
In this study, we decided to set up the assay on Erta-
penem hydrolysis as it is associated with a characteristic
peak pattern easily detected using only the organic
matrix HCCA which is used also for bacteria identifica-
tion. Furthermore, Ertapenem is considered a good
candidate for carbapenemase producers detection as re-
ported by Nordmann et al. 2012 [6, 19].
For the 55 K. pneumoniae strains studied, no false-
negative results were found. This is important, because
the aim of the assay is to obtain a rapid information for
a timely and effective antibiotic therapy.
Therefore, the test showed a high sensitivity and this
is important for an appropriate antibiotic stewardship, as
a good sensitivity allows a higher level of confidence in
the administration of narrow-spectrum antibiotics in
presence of susceptible isolates [17].
Furthermore, carbapenemase-production detection assay
was able to detect and discriminate between different
carbapenemase-producing K. pneumoniae isolates within
30 min to 3 h after incubation with Ertapenem. The rapid
detection of carbapenemase-producing bacteria from posi-
tive BCs, combined with a proactive antimicrobial steward-
ship program, is important because the choice of the
optimal therapy is crucial for the prognosis of patients with
sepsis. With the present protocol, a report regarding
the effectiveness of carbapenem therapy is obtainable
within a few hours after the BC is flagged positive.
The presence/absence of characteristic peak patterns
resulting from carbapenemase-producing and non-
carbapenemase-producing strains has been used as
the cut-off of the assay with maximum sensitivity
and specificity.
The MALDI-TOF MS-based assay and the approved
routine method provided the same classification results.
Furthermore, identification and carbapenemase-production
detection testing by MALDI-TOF MS can be performed in
parallel, as widely the same, and the additional hands-on
time required is moderate.
To evaluate whether potential residues of blood cul-
ture fluid could interfere with the reproducibility of the
measurements, the analysis was performed in quadrupli-
cate. No interference was observed.
All blaKPC positive isolates showed a peak within the
window of 11,109 ± 15 Da that was absent in all blaKPC
negative isolates of K. pneumoniae (Fig. 2). This peak
has been suggested by Lau et al. (2014) as a blaKPC-con-
taining pKpQIL plasmid-identifying proteomic marker
that could be implemented in the routine screening of
the clinical laboratory workflow and may monitoring
epidemiological dissemination mapping in real time dur-
ing any future CRE hospital outbreak [22]. These data
suggest a monoclonal spreading of all KPC-producing K.
pneumoniae isolates in our hospitals, probably correlated
to the hyper-epidemic clonal complex (CC) 258 (ST-258
producing KPC-2 or KPC-3, and ST-512 producing











31 K.pneumoniae KPC ≥8 ≥16 ≥16 + 0.5 h
5 K.pneumoniae KPC,VIM ≥8 ≥16 ≥16 + 2 h
4 K.pneumoniae OXA-48 ≥8 ≤2 ≤2 + 3 h
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KPC-3) which was considered as the predominant clone
in Italy [18]. The positive detection of ~ 11,109 Da mass
peak associated with blaKPC-containing pKpQIL plasmid
could be a real-time marker of carbapenem-producing
strains of great clinical and epidemiological value as sug-
gested by Lau et al. (2014) [22]. It could be easily imple-
mented in the routine diagnostic activity of any
microbiology laboratory as part of the organism identifi-
cation by MALDI-TOF MS without placing additional
constraints on laboratory resources. All these findings
confirm the capacity of MALDI-TOF MS technology to
identify timely a carbapenemase producer causing a
bacteremia. Compared with the molecular-based tech-
niques the cost saving is significant and no particular
skilled personnel is required [21]. In addition, a proteomic
approach unlike a genomic provides information on gene
expression without focusing on single genes. Indeed, gen-
omic assays may not reveal novel carbapenemase genes as
the range of resistance genes to be detected is predefined.
The MALDI-TOF MS carbapenemase-production de-
tection assay could be used to confirm carbapenemase
activity either in routine and reference laboratories and
might supplement other rapid and cost-effective tests
used in carbapenemase detection such as the phenotypic
Carba NP test.
However, these preliminary findings requires further
assessment and confirmation, preferably by multicenter
validation studies in order to avoid clonal bias as well
as analytical error and develop universal guidelines
for data interpretation.
Conclusion
In summary, the presented carbapenemase-producing
strain detection by MALDI-TOF MS technology could
improve the workflow of BCs positive to Enterobacte-
riaceae strains which show a suspicious susceptibility
profile, and enhance the stewardship of carbapenems
by revising the resistance surveillance program at dif-
ferent levels.
A final same-day report will be available to clinicians
and to hospital epidemiologists improving patient
management and treatment; thus, preventing out-
breaks and spreading of pathogens in the hospital with
beneficial effects on the health care system.
Compared to other alternative approaches, like
molecular-genetic methods that remain costly with
practical limitations, this method is cost effective,
highly sensitivity and easy to perform.
However, a single diagnostic technology cannot be
universally applicable in clinical microbiology as the
detection of a limited number of specific determi-
nants cannot accomplish the complex issue of anti-
biotic resistance.
Fig. 2 Identification of a MALDI-TOF MS peak associated with blaKPC. Presence of the 11,109-Da peak in KPC-carrying K. pneumoniae isolate mass
spectrum (fuchsia) and absence of an 11,109-Da peak in a K. pneumoniae non KPC-carrying isolate mass spectrum (green), respectively. This specific
peak could be a helpful real-time marker in epidemic strain detection in a hospital setting
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